ID

37052

Description

Effect of Andosan in Patients With Rheumatoid Arthritis; ODM derived from: https://clinicaltrials.gov/show/NCT01815411

Lien

https://clinicaltrials.gov/show/NCT01815411

Mots-clés

Versions (1)
  1. 01/07/2019 01/07/2019 -
Détendeur de droits

See clinicaltrials.gov

Téléchargé le

1 juillet 2019

DOI

Pour une demande vous connecter.

Licence

Creative Commons BY 4.0
Modèle Commentaires :

Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.

Retour au modèle Commentaires
Groupe Item commentaires pour :

Item commentaires pour :

Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.

Eligibility Rheumatoid Arthritis NCT01815411

Anglais

Eligibility Rheumatoid Arthritis NCT01815411

1 Formulaires  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
age>18 years
Description

Age

Type de données

boolean

Alias
UMLS CUI [1]
C0001779
able and willing to give written informed consent, and to comply with the requirements of the study protocol.
Description

Informed Consent | Protocol Compliance

Type de données

boolean

Alias
UMLS CUI [1]
C0021430
UMLS CUI [2]
C0525058
fulfilling the acr 1987 revised diagnostic criteria for the diagnosis rheumatoid arthritis.
Description

Rheumatoid Arthritis

Type de données

boolean

Alias
UMLS CUI [1]
C0003873
moderate disease activity based on the clinical evaluation including das28-esr (das28 3.2-5.1) [11, 12].
Description

Moderate disease activity DAS28

Type de données

boolean

Alias
UMLS CUI [1,1]
C2368567
UMLS CUI [1,2]
C4481729
stable medication by disease modifying drugs (dmards) and systemic glucocorticosteroids for 3 months prior to the inclusion.
Description

DMARDs Stable | Systemic Glucocorticoids Stable

Type de données

boolean

Alias
UMLS CUI [1,1]
C0242708
UMLS CUI [1,2]
C0205360
UMLS CUI [2,1]
C3540777
UMLS CUI [2,2]
C0205360
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
lack of cooperativity.
Description

Cooperative Behavior Lacking

Type de données

boolean

Alias
UMLS CUI [1,1]
C0009964
UMLS CUI [1,2]
C0332268
clinically significant chronic infection, including positive serology for hepatitis b or c, history of positive hiv status.
Description

Chronic infectious disease | Hepatitis B Seropositive | Hepatitis C Seropositive | HIV Seropositivity

Type de données

boolean

Alias
UMLS CUI [1]
C0151317
UMLS CUI [2,1]
C0019163
UMLS CUI [2,2]
C0521143
UMLS CUI [3,1]
C0019196
UMLS CUI [3,2]
C0521143
UMLS CUI [4]
C0019699
acute significant infection during the last 3 weeks before the inclusion. surgery during the last 4 weeks before the inclusion, and during the study period.
Description

Communicable Disease | Operative Surgical Procedures

Type de données

boolean

Alias
UMLS CUI [1]
C0009450
UMLS CUI [2]
C0543467
clinically significant malignancy .
Description

Malignant Neoplasms

Type de données

boolean

Alias
UMLS CUI [1]
C0006826
drug addiction
Description

Drug Dependence

Type de données

boolean

Alias
UMLS CUI [1]
C1510472
any inflammatory disease of permanence not related to ra.
Description

Inflammatory disorder Permanent | Relationship Absent Rheumatoid Arthritis

Type de données

boolean

Alias
UMLS CUI [1,1]
C1290884
UMLS CUI [1,2]
C0205355
UMLS CUI [2,1]
C0439849
UMLS CUI [2,2]
C0332197
UMLS CUI [2,3]
C0003873
use of prednisolone >7,5 mg daily for 1 month prior to the inclusion.
Description

Prednisolone U/day

Type de données

boolean

Alias
UMLS CUI [1,1]
C0032950
UMLS CUI [1,2]
C0456683
use of biologic treatment including antibodies to cytokines and their receptors for 6 weeks prior to the inclusion.
Description

Biological treatment | Antibodies Cytokine | Antibodies Cytokine Receptors

Type de données

boolean

Alias
UMLS CUI [1]
C1531518
UMLS CUI [2,1]
C3495458
UMLS CUI [2,2]
C0079189
UMLS CUI [3,1]
C3495458
UMLS CUI [3,2]
C0206552
use of intramuscular, intra-articular or intravenous injections of corticosteroids during or within 4 weeks prior to inclusion in the trial.
Description

Adrenal Cortex Hormones Intramuscular injection | Intraarticular injection of corticosteroids | Adrenal Cortex Hormones Intravenous Injection

Type de données

boolean

Alias
UMLS CUI [1,1]
C0001617
UMLS CUI [1,2]
C0021492
UMLS CUI [2]
C2064783
UMLS CUI [3,1]
C0001617
UMLS CUI [3,2]
C0021494
vaccination during the trial.
Description

Vaccination

Type de données

boolean

Alias
UMLS CUI [1]
C0042196
pregnancy or breast-feeding.
Description

Pregnancy | Breast Feeding

Type de données

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147
Retour au début de la page

Similar models

Eligibility Rheumatoid Arthritis NCT01815411

1 Formulaires
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Item Group
C1512693 (UMLS CUI)
Age
Item
age>18 years
boolean
C0001779 (UMLS CUI [1])
Informed Consent | Protocol Compliance
Item
able and willing to give written informed consent, and to comply with the requirements of the study protocol.
boolean
C0021430 (UMLS CUI [1])
C0525058 (UMLS CUI [2])
Rheumatoid Arthritis
Item
fulfilling the acr 1987 revised diagnostic criteria for the diagnosis rheumatoid arthritis.
boolean
C0003873 (UMLS CUI [1])
Moderate disease activity DAS28
Item
moderate disease activity based on the clinical evaluation including das28-esr (das28 3.2-5.1) [11, 12].
boolean
C2368567 (UMLS CUI [1,1])
C4481729 (UMLS CUI [1,2])
DMARDs Stable | Systemic Glucocorticoids Stable
Item
stable medication by disease modifying drugs (dmards) and systemic glucocorticosteroids for 3 months prior to the inclusion.
boolean
C0242708 (UMLS CUI [1,1])
C0205360 (UMLS CUI [1,2])
C3540777 (UMLS CUI [2,1])
C0205360 (UMLS CUI [2,2])
Item Group
C0680251 (UMLS CUI)
Cooperative Behavior Lacking
Item
lack of cooperativity.
boolean
C0009964 (UMLS CUI [1,1])
C0332268 (UMLS CUI [1,2])
Chronic infectious disease | Hepatitis B Seropositive | Hepatitis C Seropositive | HIV Seropositivity
Item
clinically significant chronic infection, including positive serology for hepatitis b or c, history of positive hiv status.
boolean
C0151317 (UMLS CUI [1])
C0019163 (UMLS CUI [2,1])
C0521143 (UMLS CUI [2,2])
C0019196 (UMLS CUI [3,1])
C0521143 (UMLS CUI [3,2])
C0019699 (UMLS CUI [4])
Communicable Disease | Operative Surgical Procedures
Item
acute significant infection during the last 3 weeks before the inclusion. surgery during the last 4 weeks before the inclusion, and during the study period.
boolean
C0009450 (UMLS CUI [1])
C0543467 (UMLS CUI [2])
Malignant Neoplasms
Item
clinically significant malignancy .
boolean
C0006826 (UMLS CUI [1])
Drug Dependence
Item
drug addiction
boolean
C1510472 (UMLS CUI [1])
Inflammatory disorder Permanent | Relationship Absent Rheumatoid Arthritis
Item
any inflammatory disease of permanence not related to ra.
boolean
C1290884 (UMLS CUI [1,1])
C0205355 (UMLS CUI [1,2])
C0439849 (UMLS CUI [2,1])
C0332197 (UMLS CUI [2,2])
C0003873 (UMLS CUI [2,3])
Prednisolone U/day
Item
use of prednisolone >7,5 mg daily for 1 month prior to the inclusion.
boolean
C0032950 (UMLS CUI [1,1])
C0456683 (UMLS CUI [1,2])
Biological treatment | Antibodies Cytokine | Antibodies Cytokine Receptors
Item
use of biologic treatment including antibodies to cytokines and their receptors for 6 weeks prior to the inclusion.
boolean
C1531518 (UMLS CUI [1])
C3495458 (UMLS CUI [2,1])
C0079189 (UMLS CUI [2,2])
C3495458 (UMLS CUI [3,1])
C0206552 (UMLS CUI [3,2])
Adrenal Cortex Hormones Intramuscular injection | Intraarticular injection of corticosteroids | Adrenal Cortex Hormones Intravenous Injection
Item
use of intramuscular, intra-articular or intravenous injections of corticosteroids during or within 4 weeks prior to inclusion in the trial.
boolean
C0001617 (UMLS CUI [1,1])
C0021492 (UMLS CUI [1,2])
C2064783 (UMLS CUI [2])
C0001617 (UMLS CUI [3,1])
C0021494 (UMLS CUI [3,2])
Vaccination
Item
vaccination during the trial.
boolean
C0042196 (UMLS CUI [1])
Pregnancy | Breast Feeding
Item
pregnancy or breast-feeding.
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
Retour au début de la page 

Contact

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial